Comparison of survival rates for intrathecal MTX versus ITT. (A) Five-year disease-free survival (± SE): 93.2% ± 2.1% and 90.6 % ± 2.3% (P = .85); (B) 5-year overall survival (± SE): 96.3% ± 1.5% and 96.7 % ± 1.4% (P = .77). HR, high risk; ITT, intrathecal triple therapy; MTX, methotrexate. Reprinted with permission. © 2020 American Society of Clinical Oncology. All rights reserved. Salzer WL et al. J Clin Oncol. doi:10.1200/JCO.19.02892.

Comparison of survival rates for intrathecal MTX versus ITT. (A) Five-year disease-free survival (± SE): 93.2% ± 2.1% and 90.6 % ± 2.3% (P = .85); (B) 5-year overall survival (± SE): 96.3% ± 1.5% and 96.7 % ± 1.4% (P = .77). HR, high risk; ITT, intrathecal triple therapy; MTX, methotrexate. Reprinted with permission. © 2020 American Society of Clinical Oncology. All rights reserved. Salzer WL et al. J Clin Oncol. doi:10.1200/JCO.19.02892.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal